Illumina stock (US4523271090): Shares up 10.6% YTD amid strong earnings beat

Illumina stock has climbed 10.6% since January 2026 to $145.00, fueled by a recent earnings beat with $1.15 EPS topping estimates by $0.10 and 4.8% revenue growth. Consensus rating holds at Hold.

Illumina shares advanced 10.6% year-to-date as of May 13, 2026, trading at $145.00 on Nasdaq after closing down 0.48% that day, according to MarketBeat as of 05/13/2026. The life sciences firm reported quarterly EPS of $1.15, surpassing consensus estimates of $1.05 by $0.10, with revenue up 4.8% year-over-year in the period published recently.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Illumina Inc.
• Sector/industry: Life sciences / Genomics
• Headquarters/country: San Diego, USA
• Core markets: North America, Europe, Asia
• Key revenue drivers: DNA sequencing instruments, consumables
• Home exchange/listing venue: Nasdaq (ILMN)
• Trading currency: USD

Illumina: core business model

Illumina develops and sells DNA sequencing and microarray technologies that enable researchers and clinicians to analyze genetic variations and functions at scale. The company pioneered high-speed, affordable genome reading, powering advancements in genomics research worldwide, according to Barchart as of recent publication. Its core offerings include sequencing instruments, consumables, and related services, generating recurring revenue from high-margin kits used in labs.

Headquartered in San Diego, California, Illumina serves academic institutions, biotech firms, and pharmaceutical companies. The Nasdaq-listed stock (ILMN) benefits from its dominant position in next-generation sequencing (NGS), which holds relevance for US investors through exposure to booming biotech innovation and precision medicine in the American healthcare sector.

Main revenue and product drivers for Illumina

Sequencing consumables represent the largest revenue driver, accounting for the majority of sales due to repeat purchases by customers. Instruments provide upfront sales, but ongoing kits and services ensure steady cash flow. In the latest quarter, revenue grew 4.8% year-over-year, reflecting resilient demand amid expanding genomic applications, as reported by MarketBeat as of 05/13/2026.

Key products like the NovaSeq and NextSeq systems drive growth in clinical diagnostics, oncology, and reproductive health testing. For US investors, Illumina's technology supports major advancements in personalized medicine, with strong ties to the US biotech ecosystem including partnerships with leading pharma firms.

Industry trends and competitive position

The genomics industry is expanding rapidly, driven by falling sequencing costs and rising demand for genetic data in drug discovery and population health. Illumina maintains a leading market share in NGS, though faces competition from emerging players. Its one-month return of +12.2% underscores momentum in this high-growth sector vital to US economic leadership in life sciences.

Why Illumina matters for US investors

Listed on Nasdaq, Illumina offers US investors direct exposure to genomics innovation fueling American healthcare and biotech sectors. With operations centered in the US and significant revenue from domestic markets, the company aligns with trends in precision medicine and AI-driven biology analysis.

Conclusion

Illumina's stock has shown solid year-to-date gains, supported by an earnings beat and sustained demand for its sequencing technologies. While analysts maintain a Hold consensus, the company's role in genomics positions it amid key industry growth drivers. Investors track upcoming quarters for continued execution in a competitive landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.